Current treatment options for primary aldosteronism are limited to surgery or mineralocorticoid receptor antagonists when surgery isn't an option. In a phase IIa trial, baxdrostat resolved or reduced ...
An investigational antihypertensive drug resolved or reduced hypertension in patients with primary aldosteronism, according to a small phase IIa trial. By week 12, systolic blood pressure was reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results